PrevengHo-Vir Homeoprohylaxis COVID-2019

Homeoprophylaxis safety study with PrevengHo®-Vir in the context of the COVID-19 pandemic in Cuba. Quasi-experimental study post-registration (COVID-19) - PREVENGHO-COVID

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

RPCEC

Registry ID

RPCEC00000312

Enrollment

180

Registered

2020-05-13

Start date

2020-04-29

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-2019 COVID-19 SARS-CoV-2

Interventions

The homeopathic remedy PrevengHo®-Vir will be used. Five drops diluted in two ounces of drinking water will be administered, once a day for three consecutive days and another single dose one week late

Homeopathic Remedy

Administration, Oral

PrevengHo®-Vir

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Individuals between 18 and 64 years of age. 2. Individuals without any respiratory symptoms at the time of administration of PrevengHo®-Vir.

Exclusion criteria

Exclusion criteria: 1. Individuals allergic to any of the components of the homeopathic medicine.

Design outcomes

Primary

Measure	Time frame
Safety (Safety of the product for each patient once the safety assessment stage has been completed. Yes: once this stage is completed, the patient will not have any type of adverse event (AE), or those who will report are mild, related or not to PrevengHo®-Vir. No: once this stage was completed, the patient reported any AE with moderate or severe intensity, severe or non-severe, related to PrevengHo®-Vir). Measurement time: Close of the sixth week.	—

Measure

Time frame

Safety (Safety of the product for each patient once the safety assessment stage has been completed. Yes: once this stage is completed, the patient will not have any type of adverse event (AE), or those who will report are mild, related or not to PrevengHo®-Vir. No: once this stage was completed, the patient reported any AE with moderate or severe intensity, severe or non-severe, related to PrevengHo®-Vir). Measurement time: Close of the sixth week.

—

Secondary

Measure	Time frame
1. Type of Adverse Event-AE (Clinical manifestations that appear as an unwanted effect; according to symptoms, signs and syndromes). Measurement time: Weekly, during the first six weeks of the study. 2. Severity (Risk of the effect caused by an AE in an individual. Serious: Death of the patient, threat to the life of the subject, requires hospitalization or prolongs an existing hospitalization, produces significant or persistent disability/invalidity. Non-serious: Does not meet any of the above requirements). Measurement time: Weekly, during the first six weeks of the study. 3. Intensity (Graduation in which an AE can be presented. Mild: It is well tolerated, causes minimal discomfort and does not interfere with daily activities. Moderate: Annoying enough to prevent or interfere with daily activities. Severe: Prevents daily activities). Measurement time: Weekly, during the first six weeks of the study. 4. Imputability (Degree of medication-AE association, according to the algorithm of Karch and Lasagna. Definitive: Clinical event that occurs in a plausible temporal relationship with the administration of the drug, which cannot be explained by the disease, another drug, or another chemical, disappears when the drug is withdrawn and reappears with the re-exposure to the drug. Likely: The above conditions are met except that there is no re-exposure or the information is unknown. Possible: Clinical event, with a reasonable time sequence with the administration of the drug, which can also be explained by the disease, another drug or another chemical substance, the information about the suspension of the use of the drug may be absent or not clear. Not related to the clinical event: It has no causal relationship with the product used). Measurement time: Weekly, during the first six weeks of the study. 5. Outcome of the AE in relation to the patient (Final situation that the patient arrives after having the EA. Recovered: The patient resolved the EA and recovered his st	—

Measure

Time frame

1. Type of Adverse Event-AE (Clinical manifestations that appear as an unwanted effect; according to symptoms, signs and syndromes). Measurement time: Weekly, during the first six weeks of the study. 2. Severity (Risk of the effect caused by an AE in an individual. Serious: Death of the patient, threat to the life of the subject, requires hospitalization or prolongs an existing hospitalization, produces significant or persistent disability/invalidity. Non-serious: Does not meet any of the above requirements). Measurement time: Weekly, during the first six weeks of the study. 3. Intensity (Graduation in which an AE can be presented. Mild: It is well tolerated, causes minimal discomfort and does not interfere with daily activities. Moderate: Annoying enough to prevent or interfere with daily activities. Severe: Prevents daily activities). Measurement time: Weekly, during the first six weeks of the study. 4. Imputability (Degree of medication-AE association, according to the algorithm of Karch and Lasagna. Definitive: Clinical event that occurs in a plausible temporal relationship with the administration of the drug, which cannot be explained by the disease, another drug, or another chemical, disappears when the drug is withdrawn and reappears with the re-exposure to the drug. Likely: The above conditions are met except that there is no re-exposure or the information is unknown. Possible: Clinical event, with a reasonable time sequence with the administration of the drug, which can also be explained by the disease, another drug or another chemical substance, the information about the suspension of the use of the drug may be absent or not clear. Not related to the clinical event: It has no causal relationship with the product used). Measurement time: Weekly, during the first six weeks of the study. 5. Outcome of the AE in relation to the patient (Final situation that the patient arrives after having the EA. Recovered: The patient resolved the EA and recovered his st

—

Countries

Cuba

Contacts

Public ContactJohann Perdomo Delgado

Department of Natural and Traditional Medicine, Ministry of Public Health, Republic of Cuba

tradicional@msp.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026